Literature DB >> 30475440

Combined liver-kidney transplantation for primary hyperoxaluria type I in children: Single Center Experience.

Magd A Kotb1,2, Alaa F Hamza2,3, Hesham Abd El Kader2,3, Magda El Monayeri2,4, Dalia S Mosallam1, Nazira Ali1,2, Christine William Shaker Basanti1, Hafez Bazaraa1,5,6, Hany Abdelrahman7, Marwa M Nabhan1,5,6, Hend Abd El Baky1,2, Sally T Mostafa El Sorogy8, Inas E M Kamel9, Hoda Ismail2,10, Yasmin Ramadan1,5,6, Safaa M Abd El Rahman1,5,7, Neveen A Soliman1,5,6.   

Abstract

Primary hyperoxalurias are rare inborn errors of metabolism with deficiency of hepatic enzymes that lead to excessive urinary oxalate excretion and overproduction of oxalate which is deposited in various organs. Hyperoxaluria results in serious morbid-ity, end stage kidney disease (ESKD), and mortality if left untreated. Combined liver kidney transplantation (CLKT) is recognized as a management of ESKD for children with hyperoxaluria type 1 (PH1). This study aimed to report outcome of CLKT in a pediatric cohort of PH1 patients, through retrospective analysis of data of 8 children (2 girls and 6 boys) who presented by PH1 to Wadi El Nil Pediatric Living Related Liver Transplant Unit during 2001-2017. Mean age at transplant was 8.2 ± 4 years. Only three of the children underwent confirmatory genotyping. Three patients died prior to surgery on waiting list. The first attempt at CLKT was consecutive, and despite initial successful liver transplant, the girl died of biliary peritonitis prior to scheduled renal transplant. Of the four who underwent simultaneous CLKT, only two survived and are well, one with insignificant complications, and other suffered from abdominal Burkitt lymphoma managed by excision and resection anastomosis, four cycles of rituximab, cyclophosphamide, vincristine, and prednisone. The other two died, one due to uncontrollable bleeding within 36 hours of procedure, while the other died awaiting renal transplant after loss of renal graft to recurrent renal oxalosis 6 months post-transplant. PH1 with ESKD is a rare disease; simultaneous CLKT offers good quality of life for afflicted children. Graft shortage and renal graft loss to oxalosis challenge the outcome.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  4-hydroxy-2-oxoglutarate aldolase enzyme; Primary hyperoxaluria type 1 (PH1); combined liver-kidney transplantation; end-stage kidney disease (ESKD); glyoxylate reductase; hydroxypyruvate reductase; liver-specific alanine-glyoxylate aminotransferase

Mesh:

Year:  2018        PMID: 30475440     DOI: 10.1111/petr.13313

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  8 in total

Review 1.  Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era.

Authors:  Neveen A Soliman; Sameh Mabrouk
Journal:  Clin Kidney J       Date:  2022-05-17

2.  Extreme living donation: A single center simultaneous and sequential living liver-kidney donor experience with long-term outcomes under literature review.

Authors:  Yücel Yankol; Cihan Karataş; Turan Kanmaz; Burak Koçak; Münci Kalayoğlu; Koray Acarlı
Journal:  Turk J Surg       Date:  2021-09-28

3.  Combined liver-kidney transplant in a 21-month-old child with type 1 primary hyperoxaluria-The perioperative challenges.

Authors:  Nidhin Eldo; Sangeeth P Srinivasan; Nisha Rajmohan; Mathew Jacob
Journal:  Indian J Anaesth       Date:  2020-05-01

Review 4.  Calcium oxalate crystal deposition in the kidney: identification, causes and consequences.

Authors:  R Geraghty; K Wood; J A Sayer
Journal:  Urolithiasis       Date:  2020-07-27       Impact factor: 3.436

5.  Clinical and molecular characterization of primary hyperoxaluria in Egypt.

Authors:  Neveen A Soliman; Mohamed A Elmonem; Safaa M Abdelrahman; Marwa M Nabhan; Yosra A Fahmy; Andrea Cogal; Peter C Harris; Dawn S Milliner
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

6.  Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.

Authors:  Elisabeth L Metry; Liza M M van Dijk; Hessel Peters-Sengers; Michiel J S Oosterveld; Jaap W Groothoff; Rutger J Ploeg; Vianda S Stel; Sander F Garrelfs
Journal:  Pediatr Nephrol       Date:  2021-04-08       Impact factor: 3.714

7.  Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient.

Authors:  Caroline Kempf; Anja Pfau; Johannes Holle; Karen Müller-Schlüter; Philip Bufler; Felix Knauf; Dominik Müller
Journal:  Pediatr Nephrol       Date:  2020-05-16       Impact factor: 3.714

Review 8.  Combined liver-kidney transplantation for rare diseases.

Authors:  Mladen Knotek; Rafaela Novak; Alemka Jaklin-Kekez; Anna Mrzljak
Journal:  World J Hepatol       Date:  2020-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.